Published: Apr 21, 2021
Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) in a single device.
With this new European authorization, Chiesi reinforces its commitment to providing a broad portfolio of formulations and devices to COPD patients.
PARMA, Italy, April 21, 2021 (GLOBE NEWSWIRE) -- Chiesi, an international research-focused healthcare group (Chiesi Group), today announced that the European Commission has granted the marketing authorization for Trimbow® inhalation powder delivered through NEXThaler (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium), an extrafine formulation triple fixed combination therapy in a single dry powder inhaler (DPI), for the maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.